Processing Magazine

Court Blocks Rivals from Selling Momenta Generic

November 1, 2011

Momenta Pharmaceuticals Inc. won a federal court ruling on Friday that temporarily blocks other companies from selling a generic version of its anti-clotting drug, reports the Associated Press. U.S. District Court Judge Nathaniel M. Gorton in Boston ordered other companies not to sell their generic version of anticoagulant Lovenox until a patent lawsuit filed by Momenta is settled. Since July 2010, Momenta has made the only approved generic version of Lovenox, a drug used to prevent deep-vein blood clots from forming in the legs of patients on bed rest, including those having hip replacement or knee replacement surgery. Momenta claims that a version developed by Amphastar Pharmaceuticals Inc., and recently approved by the U.S. Food and Drug Administration, infringes on a Momenta patent. The judge granted Momenta''s request for an injunction blocking Amphastar, Watson Pharmaceuticals Inc. and an Amphastar subsidiary, International Medication Systems Ltd., from selling their version until the end of the patent lawsuit.